OFI Invest Asset Management Increases Position in AbbVie Inc. $ABBV

11 Apr 2026, 10:00 by Tristan Rich · The Markets Daily

OFI Invest Asset Management boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 15.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 278,991 shares of the company’s stock after acquiring an additional 36,486 shares during the period. OFI Invest Asset Management’s holdings in AbbVie were worth $64,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Evolution Wealth Management Inc. purchased a new stake in AbbVie during the 2nd quarter valued at about $26,000. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the 3rd quarter valued at approximately $31,000. Finally, Caitlin John LLC purchased a new stake in shares of AbbVie in the 3rd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $208.22 on Friday. The stock has a market capitalization of $368.16 billion, a P/E ratio of 88.23, a PEG ratio of 0.76 and a beta of 0.38. The company has a 50 day moving average price of $220.35 and a 200 day moving average price of $224.01. AbbVie Inc. has a fifty-two week low of $168.54 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Piper Sandler increased their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Cantor Fitzgerald dropped their price target on shares of AbbVie from $250.00 to $240.00 and set an “overweight” rating for the company in a research note on Wednesday. Barclays assumed coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Guggenheim increased their price target on shares of AbbVie from $242.00 to $249.00 and gave the company a “buy” rating in a research note on Friday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.00.

Check Out Our Latest Stock Analysis on ABBV

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
Positive Sentiment: Analysts and features continue to highlight AbbVie’s successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges ‘outdated’ 340B drug discount program guidance in new lawsuit
Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie’s guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie’s guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company’s stock.

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.